Abstracts tagged "Activity score"

Abstract Number: 2664 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Tracks Responses in Patients with Rheumatoid Arthritis Treated with Either Adalimumab, Etanercept, and Infliximab
Shintaro Hirata¹, Douglas J. Haney², Guy Cavet², Rebecca Bolce², Wanying Li², Nadine Defranoux², David Chernoff², Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose : Anti-TNF therapy has become a standard therapeutic strategy for treatment of patients with rheumatoid arthritis (RA). A validated multi-biomarker disease activity algorithm (MBDA) blood…
Abstract Number: 1044 • 2012 ACR/ARHP Annual Meeting
Ultrasound Scores of Enthesitis and Dactylitis Do Not Correlate with Corresponding Clinical Findings in Psoriasis Arthritis
Rusmir Husic¹, Josef Hermann¹, Judith Gretler², Winfried B. Graninger³ and Christian Dejaco⁴, ¹Rheumatology, Medical University Graz, Graz, Austria, ²Med Univ Klinik Graz, Auenbruggerplatz 15, Graz, Austria, ³Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: To compare sonography verified inflammation of entheses, tendons and joints with corresponding clinical findings in psoriasis arthritis (PsA) patients. Methods: Prospective study of 70 consecutive…
Abstract Number: 691 • 2012 ACR/ARHP Annual Meeting
Characterization of Pro-Inflammatory Cytokines and Vitamin D Levels in a Lupus Cohort and Correlation with Disease Activity
Rohan Willis¹, Praveen Jajoria¹, Brock E. Harper², Emilio B. Gonzalez³, Michelle Petri⁴, Ehtisham Akhter⁵, Hong Fang⁴ and Silvia S. Pierangeli¹, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Med/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Multiple cytokines play a role in the immune dysregulation seen in systemic lupus erythematosus (SLE) and the local inflammatory responses that ultimately lead to…
Abstract Number: 563 • 2012 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis, a Decrease in MRI Spinal Inflammation Predicts Improvement in Spinal Mobility Independently of Patient Reported Symptomatic Improvement
Pedro Machado¹, Robert Landewé², Jürgen Braun³, Xenofon Baraliakos⁴, Kay-Geert A. Hermann⁵, Benjamin Hsu⁶, Daniel Baker⁷ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ³PsAID taskforce, EULAR, Zurich, Switzerland, ⁴Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Research and Development, Centocor Inc., Malvern/Philadelphia, PA
Background/Purpose: It has been previously shown that spinal mobility in ankylosing spondylitis (AS) is associated with the level of inflammation of the spine. However an…
Abstract Number: 546 • 2012 ACR/ARHP Annual Meeting
The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti-TNF in Spondyloarthritis Patients
Chamaida Plasencia¹, Dora Pascual-Salcedo², Sara Garcia-Carazo³, Gema Bonilla⁴, Leticia Lojo⁵, Laura Nuño⁶, Alejandro Villalba⁷, Diana Peiteado⁷, Concepcion Castillo-Gallego⁷, Florencia Arribas², Daniel Nagore⁸, E. Martin-Mola⁹ and Alejandro Balsa⁴, ¹Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain, ²Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ³La PAZ University Hospital, RHEUMATOLOGY UNIT, Spain, Spain, ⁴Rheumatology, Hospital La Paz, Madrid, Spain, ⁵Rheumatology, Hospital Universitario La Paz, Spain, Spain, ⁶Hospital La Paz-IdiPaz, Madrid, Spain, ⁷Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁸Proteomika S.L., ⁹Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Spondyloarthropathies (SpAs) encompass a heterogeneous group of diseases that primarily affect the axial skeleton and entheses. Although anti-TNF drugs have proven to be effective…
Abstract Number: 421 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not Antibodies to Citrullinated Proteins, Are Associated with High Disease Activity
Josef S. Smolen¹, Farideh Alasti² and Daniel Aletaha³, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Autoantibodies in general, and rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) in particular, are a hallmark of RA. After their characterization, ACPA have…
Abstract Number: 2609 • 2012 ACR/ARHP Annual Meeting
Construct and Criterion Validity of Several Proposed DAS28 Based Rheumatoid Arthritis Flare Criteria: A Cohort Validation Study
Aatke van der Maas¹, Elisabeth Lie², Robin Christensen³, Ernest Choy⁴, Yaël A. de Man⁵, Piet L.C.M. van Riel⁶, Thasia G. Woodworth⁷ and Alfons A. den Broeder¹, ¹Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁵Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Medicine, Division of Rheumatology, Visiting Clinical Researcher, Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: To enable consistent assessment of impact of tapering, withdrawal and dose optimization strategies, there is an increasing need for validated measures of flare in…
Abstract Number: 393 • 2012 ACR/ARHP Annual Meeting
Defining Criteria for Rheumatoid Arthritis Patient-Derived Disease Activity Score That Corrresponds to Disease Activity Score 28 and Clnical Disease Activity Index Based Statuses and Response Criteria
Alexander MH Leung¹, Daniel Farewell², Chak S. Lau³ and Ernest Choy⁴, ¹Department of Rheumatology, Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Primary Care and Public Health, Cardiff, ENGLAND, United Kingdom, ³Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Patient-based disease activity score (PDAS1 [with ESR] & PDAS2 [without ESR]) in rheumatoid arthritis (RA) are validated patient reported outcome measures of disease activity.…
Abstract Number: 2618 • 2012 ACR/ARHP Annual Meeting
Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy
Eduardo F. Borba¹, Sandra G. Pasoto¹, Ana L. Calich¹, Ricardo Fuller¹, Vilma S.T. Viana¹, Margareth Vendramini¹, Joao Miraglia², Maria A. Ishida³ and Eloisa Bonfa⁴, ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Instituto Butantan, Fundação Butantan, São Paulo, Brazil, ³Instituto Adolfo Lutz, São Paulo, Brazil, ⁴Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: To determine the influence of disease activity without the effect of drugs in pandemic 2009 influenza A (H1N1) vaccine immune response in untreated systemic…
Abstract Number: 402 • 2012 ACR/ARHP Annual Meeting
Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and Relationship with Disease Activity
Rebecca Belsom¹, Archana Jain¹, Jeffrey R. Curtis², Shuo Yang³, Ted R. Mikuls⁴, Lang Chen⁵ and Angelo L. Gaffo⁶, ¹Rheumatology, University of Alabama, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Discrepancies between erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) elevations with clinical disease activity frequently occur in rheumatoid arthritis (RA) patients and may…
Abstract Number: 2348 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP
EM McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: In PMR careful tailoring of the glucocorticoid dosage to the patients needs is crucial to avoid the risk of treatment-related adverse effects and the…
Abstract Number: 319 • 2012 ACR/ARHP Annual Meeting
Gamma Interferon-Induced Protein-10 (IP-10) As a Potential Biomarker for Disease Activity in Pediatric Localized Scleroderma
Katherine Kurzinski¹, Carol A. Feghali-Bostwick², Christina Kelsey¹, Kelsey Magee³ and Kathryn S. Torok⁴, ¹Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is an autoimmune disease affecting the skin and underlying tissue. Cutaneous findings assist in categorizing the patients into active or…
Abstract Number: 2121 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Yoshiya Tanaka¹, Kentaro Hanami², Hisashi Tasaka¹, Shunsuke Fukuyo¹, Douglas J. Haney³, Nadine Defranoux³, Rebecca Bolce³, Guy Cavet³, David Chernoff³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Shintaro Hirata¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with…
Abstract Number: 277 • 2012 ACR/ARHP Annual Meeting
Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity
Katia T. Kozu¹, Clovis Artur Silva², Eloisa Bonfa³, Adriana M. Sallum⁴, Rosa M.R. Pereira⁵, Vilma S. Viana⁶, Eduardo F. Borba⁷ and Lucia M. A. Campos⁴, ¹Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, University of São Paulo, São Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Dyslipidemia has been infrequently investigated in pediatric population with autoimmune rheumatic diseases. However, lipid abnormalities in these diseases may occur due to multiple risk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.